Navigation Links
Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
Date:5/3/2013

SAN DIEGO, May 3, 2013 /PRNewswire/ -- Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.

Under terms of the agreement, Ambrx will receive an upfront payment of $15 million, funding for discovery and research activities, and potential development, regulatory and sales based milestone payments of up to $97 million per product resulting from the collaboration. Bristol- Myers Squibb will receive worldwide rights to develop and commercialize products resulting from the collaboration, and Ambrx is eligible to receive royalties on net sales. Additional terms were not disclosed.

"Bristol-Myers Squibb is a global biopharmaceutical leader with expertise developing and commercializing novel medicines for the treatment of cancer and other diseases, and we are pleased to enter into a third collaboration with the company to include another aspect of our technology platform," said Lawson Macartney , Ph.D., chief executive officer of Ambrx. "We look forward to working together to further utilize Ambrx's technology to discover and advance these antibody drug conjugates for oncology indications."

Ambrx and Bristol-Myers Squibb entered into two separate agreements in September 2011 to research, develop and commercialize biologics created with Ambrx's protein medicinal chemistry technology. These therapeutic candidates, which target the Fibroblast Growth Factor 21 (FGF-21) protein for the potential treatment of type 2 diabetes, and the Relaxin hormone for the potential treatment of heart failure, are being developed by Bristol-Myers Squibb.

About Ambrx
Ambrx Inc. is a clinical stage biopharmaceutical company using an expande
'/>"/>

SOURCE Ambrx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
8. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
9. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
10. Empire Asset Management Co. Initiates Coverage on Transcept Pharmaceuticals Inc., (NASDAQ: TSPT)
11. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)...  - MediaLINC unlocks the real ... general availability of MediaLINC - its innovative ... education, entertainment and clinical content direct to standard HD ... " Lincor has already been phenomenally ... bedside smart devices, " comments Dan Byrne , ...
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... ("CTI") (NASDAQ and MTA: CTIC) announced today the results from ... 2011. At the meeting, shareholders approved the proposal to amend ... total number of authorized shares and authorized shares of common ... Headquartered in Seattle, CTI is a biopharmaceutical ...
... June 17, 2011 The St. Francis Heart Center ... first post-FDA approval surgery in the United States using a new ... Contour 3D™ Annuloplasty Ring, the device, which is manufactured by ... the natural valve,s shape and size. The procedure ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 2Franciscan St. Francis Heart Center Surgeon Pioneers Use of Heart Valve Repair Ring 3
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide and ... from legally blind to perfect 20/20 vision has caught the ... “There is a huge portion of the population today that ... people just think that’s the way it will always be ... pretty risky at times,” reports Michaels. “This program is a ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... DENVER For the first time an oncogenic somatic ... during transfection) protein has been identified in small cell ... mutation within SCLC cell lines produced increased intracellular signaling ... form of lung cancer representing 15% of all lung ... representing 85% of lung cancer, has been extensively examined ...
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... in two years, California researcher says , , FRIDAY, Feb. 1 ... the progress of the disease in 90 percent of the ... turned the cancer into a chronic, manageable disease," said W. ... Feb. 1 issue of Cancer Research . , Twenty ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... 1 Lifespring Health,sponsors the Kaiser Permanente San Francisco ... charity event benefiting the Hemophilia Foundation of,Northern California, Support ... House., Set to take place on Feb. 3, ... course is ranked as one of the most scenic,in ...
... Piwek to Assist in Generating New Retail Licensing ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), a ... patented dermatology,products with their proprietary polymer delivery system ... selected as a new member of,the Company,s Board ...
... and vigilance show a relationship with core body temperature ... high during the daytime, skin temperature is low, which ... temperature is low at night time, skin temperature is ... suffering from narcolepsy, however, direct manipulations of their skin ...
... , UCLA and University of North Carolina researchers have found ... sexual and/or physical abuse may have a heightened brain response ... IBS is a condition that affects 10 to 15 percent ... constipation or both. , Researchers used brain ...
Cached Medicine News:Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
... Introducing the new PRONEB® ULTRA compressor. This ... time while delivering more medication to the ... LC PLUS® or PARI LC STAR® Reusable ... optimized for inhalation and retention into the ...
... PRONEB® ULTRA compressor. This high output compressor ... more medication to the patient's lungs. When ... PARI LC STAR® Reusable Nebulizer, the particle ... and retention into the lungs. With less ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
... Air., ,Allied Healthcares Timeter® PCS 414 portable ... air compressors that you may wonder if its ... 414 features a durable, mar-resistant steel case thats ... weighs only 26.5 pounds. The PCS 414 has ...
Medicine Products: